STRO — Sutro Biopharma Cashflow Statement
0.000.00%
- $307.96m
- -$5.26m
- $153.73m
- 45
- 17
- 56
- 33
Annual cashflow statement for Sutro Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -55.7 | -32.1 | -106 | -119 | -107 |
Depreciation | |||||
Non-Cash Items | 9.21 | -28.5 | 36.6 | 12.7 | 22.7 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -23.3 | -11.5 | -17.6 | 104 | -34.4 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -65 | -67.8 | -81.7 | 3.55 | -112 |
Capital Expenditures | -3.48 | -7.13 | -15.3 | -7.86 | -4.32 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -47.6 | 7.73 | -82 | -27.2 | 0.391 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -51.1 | 0.604 | -97.3 | -35 | -3.92 |
Financing Cash Flow Items | 0.636 | -0.314 | 0.778 | -0.463 | 138 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -4.18 | 269 | 3.26 | 48.3 | 138 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -120 | 202 | -176 | 16.8 | 22 |